IN2014MU01042A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MU01042A IN2014MU01042A IN1042MU2014A IN2014MU01042A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A IN 1042MU2014 A IN1042MU2014 A IN 1042MU2014A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A
- Authority
- IN
- India
- Prior art keywords
- compositions
- component
- relates
- dabigatran
- patients
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 abstract 1
- 229960003850 dabigatran Drugs 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1042MU2014 IN2014MU01042A (de) | 2014-03-26 | 2015-03-26 | |
| PCT/IN2015/000142 WO2015145462A1 (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical compositions of dabigatran |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1042MU2014 IN2014MU01042A (de) | 2014-03-26 | 2015-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MU01042A true IN2014MU01042A (de) | 2015-10-02 |
Family
ID=54194086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1042MU2014 IN2014MU01042A (de) | 2014-03-26 | 2015-03-26 |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2014MU01042A (de) |
| WO (1) | WO2015145462A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017103945A1 (en) * | 2015-12-15 | 2017-06-22 | Strides Shasun Limited | Pharmaceutical compositions |
| WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
| TR201617984A2 (tr) * | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin farmasöti̇k kompozi̇syonlari |
| TR201706848A2 (tr) | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| WO2019004980A2 (en) | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE |
| TR201722323A2 (tr) * | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari |
| TR201722630A2 (de) * | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
| TR201905308A2 (tr) * | 2019-04-09 | 2020-10-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A capsule formulation of dabigatran etexilate |
| WO2025046547A1 (en) * | 2023-09-01 | 2025-03-06 | Glenmark Pharmaceuticals Limited | A stable solid oral dosage form of dabigatran |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| JP3716901B2 (ja) | 1999-04-14 | 2005-11-16 | シオノギクオリカプス株式会社 | セルロースエーテルフィルム |
| PT1870100E (pt) | 2002-03-07 | 2012-04-17 | Boehringer Ingelheim Int | Metanossulfonato de 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo |
| DE10337697A1 (de) | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| US20130052262A1 (en) | 2010-03-01 | 2013-02-28 | Sandra Brueck | Dabigatran etexilate-containing oral pharmaceutical composition |
| WO2013110567A1 (en) | 2012-01-24 | 2013-08-01 | Boehringer Ingelheim International Gmbh | Novel orally administered dabigatran formulation |
| DK2817000T3 (da) | 2012-02-21 | 2021-10-11 | Towa Pharmaceutical Europe S L | Orale farmaceutiske sammensætninger af dabigatranetexilat |
-
2015
- 2015-03-26 IN IN1042MU2014 patent/IN2014MU01042A/en unknown
- 2015-03-26 WO PCT/IN2015/000142 patent/WO2015145462A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015145462A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MU01042A (de) | ||
| EP3206706A4 (de) | Stabile injizierbare zusammensetzung aus pharmazeutisch aktiven wirkstoffen und verfahren zu deren herstellung | |
| PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| EP3295952A4 (de) | Pharmazeutische formulierung mit glp-1-analog und herstellungsverfahren dafür | |
| EP3093023A4 (de) | Pharmazeutische zusammensetzung zur krebsbehandlung und pharmazeutische zubereitung zur krebsbehandlung mit dieser zusammensetzung als wirkstoff | |
| ZA201605379B (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| IL260766B (en) | Continuous production of complexes containing active pharmaceutical ingredients | |
| WO2014122460A3 (en) | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes | |
| EP3347022A4 (de) | Pharmazeutische zusammensetzung mit dutasterid und kapselformulierung damit | |
| SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
| EP3167893A4 (de) | Pharmazeutische zusammensetzung mit spirulina-maxima-extrakt als wirkstoff zur vorbeugung und behandlung von netzhauterkrankungen | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| EP3219311A4 (de) | Pharmazeutische zusammensetzung mit dabigatranetexilat und herstellungsverfahren, feste zubereitung und verwendung davon | |
| IL261929B (en) | Stable pharmaceutical preparations for topical administration and their use | |
| ZA201901004B (en) | High drug loaded tablet composition for treating hiv | |
| IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
| SG10201810362SA (en) | Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition | |
| WO2016083315A8 (en) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases | |
| NZ727876A (en) | Misoprostol dispersible tablet | |
| WO2015126151A3 (ko) | 신곡 추출물을 포함하는 상처 치료용 조성물 | |
| IN2013MU02585A (de) | ||
| ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
| HK40025080A (en) | A vector and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof, as well as the related therapeutic treatment method |